IMT Header

Short Courses*

Tuesday, August 25
6:30-9 PM

Targeting the Cancer Mutanome

TOPICS AND SPEAKERS:


Targeting the Cancer Mutanome
Emerging sequencing and bioinformatics technologies are now giving researchers new perspectives on the mutations in patient specific antigens, now collectively known as the cancer mutanome. Our dinner short course offers academic and industry perspectives on the analytical and computational methods used to identify neo-epitopes within a mutanome that are candidates for therapeutic intervention – and the potential applications of this knowledge in patient diagnostics and immunotherapy. An open discussion format will allow those working in this space to share insights and experiences on how to advance this new field into clinical practice.

Background and Update on Current Science
Radvanyi LaszloCourse Leader: Laszlo Radvanyi, Ph.D., Chief Scientific Officer, Lion Biotechnologies
An overview on the emerging field of neo-antigen (mutanome) targeting will be presented. This overview will summarize the current approaches used to deduce cancer neo-antigen epitopes for immunological targeting, specific examples of how neo-antigen targeting is being used already in cancer immunotherapy, some of the obstacles being faced in the field, and the impact of neo-antigen targeting will have in the future of immunotherapy.

Neo-antigens in Cancer Immunotherapy
Lelia DelamarreLelia Delamarre, Ph.D., Scientist, Cancer Immunology, Genentech (Confirmed)
Tumors accumulate mutations, which can be recognized as foreign and induce immune responses. We developed a novel strategy to identify neoepitopes by combining whole-exome sequencing and mass spectrometry analysis, along with structural prediction for discovery of immunogenic antigens. This information can be used for the immuno-monitoring of cancer patients, and help identify which patients will benefit from immunotherapy. Finally this knowledge could be exploited for the design of personalized vaccines.

Identifying Suitable Neoepitopes – Seeing Through the Fog of Suppression
Pramod SrivastavaPramod Srivastava, M.D., Ph.D., Professor, Immunology and Medicine, University of Connecticut School of Medicine; Director, Carole and Ray Neag Comprehensive Cancer Center (Confirmed)
Results of experiments, which do or do not eliminate the effect of immune suppression, while screening for immunogenic protective neoepitopes, shall be presented and discussed.


What T Cells See on Human Cancer
Marit van BuurenMarit van Buuren, MSc, Ph.D. Student, Cancer Immunology, Netherlands Cancer Institute (Confirmed; Unpublished data)
Human tumors are characterized by large numbers of mutations, of which many hundreds can be contained within expressed genes, resulting in so-called “neo-antigens”. The immune recognition of these antigens is hypothesized to be of significant importance to the activity of clinically used immunotherapeutics in melanoma. With the use of in-house developed technologies to monitor T cell reactivity, we have shown that the T cell recognition of neo-antigens is a common feature in human melanoma.

Thursday, August 27
6-9 PM

Adoptive Therapy with CAR T Cells

 
Ben BoyerinasInstructor: Ben Boyerinas, Ph.D., Scientist II, Cellular and Molecular Immunotherapy, bluebird bio  

Adoptive cell therapy (ACT) is causing a great deal of excitement in the clinical research community due to its ability to utilize a patient’s own immune cells to effectively recognize and attack cancer cells. One well-studied modality of ACT employs genetically modified chimeric antigen receptor expressing T cells (CAR T) to target surface proteins overexpressed on cancer cells. This strategy is unique from other forms of ACT, as target recognition is not MHC restricted. CAR T cells have demonstrated significant clinical potency in the treatment of certain leukemias, and trials targeting solid tumor indications are now commencing.

This short course will address:

  • History of CAR T development
  • Strategies for effective gene delivery
  • Cell production platforms and processes
  • Initial clinical successes treating acute lymphoblastic leukemia
  • Associated toxicities and clinical management
  • Challenges associated with targeting solid tumor antigens
  • The dilemma posed by the solid tumor microenvironment
  • Novel CAR T designs and technologies

*Separate registration is required.

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 


2015 IMVACS-The Immunotherapies & Vaccine Summit

Download Brochure 

2015 Final Agenda

View All Sponsors 

View Media Partners 

Exhibit Contract 


ImVacS Attendee Profile Icon 

See Who Attended ImVacS 2014! 



ImVacS Attendee Profile Statistics Attendee Profile: Over 300 international delegates from biotech, pharma, and more attend ImVacS every year. Don't miss networking and collaboration opportunities with vaccine and immunotherapy thought-leaders! View full details here.